Tra­vere miss­es pri­ma­ry end­point in PhI­II for rare kid­ney dis­ease but the com­pa­ny is still con­sid­er­ing a 'path for­ward'

Tra­vere Ther­a­peu­tics’ drug sparsen­tan didn’t hit the pri­ma­ry end­point in a Phase III study in a rare kid­ney dis­ease, but nei­ther the com­pa­ny nor an­a­lysts have writ­ten it off as a com­plete fail­ure.

The study looked at sparsen­tan in fo­cal seg­men­tal glomeru­loscle­ro­sis (FS­GS), a rare kid­ney dis­ease that leads to scar­ring of the kid­ney, re­sult­ing in pro­tein­uria and rapid de­cline in kid­ney func­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER